Xiamen YangShengTang Biotechnic

Xiamen Wantai Biological Pharmacy, a key subsidiary of the YangShengTang Group, is a leading Chinese biotechnology company specializing in the development and commercialization of innovative vaccines and diagnostic solutions. The company achieved global recognition for developing Hecolin, the world's first vaccine for Hepatitis E, and Cecolin, the first domestic Chinese HPV vaccine. Wantai utilizes a proprietary Escherichia coli-based recombinant protein expression platform to produce high-quality biologics at a competitive scale. Their extensive product portfolio includes diagnostic kits for infectious diseases such as HIV, Hepatitis, and COVID-19, alongside a robust pipeline of next-generation vaccines. Headquartered in Xiamen, the company maintains a long-standing strategic partnership with Xiamen University to drive research in public health and infectious disease prevention. Wantai is publicly traded on the Shanghai Stock Exchange and remains a critical player in expanding global access to essential immunizations.